Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gazyva

Roche Basel Switzerland

Roche to buy cancer data firm Flatiron for $1.9bn

Data provides a wealth of RWE opportunities

Roche Basel Switzerland

NICE backs Roche’s Gazyvaro after initial rejection

An undisclosed discount swayed the cost-effectiveness body

- PMLiVE

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Boehringer Ingelheim’s Ofev subject to same conditions

- PMLiVE

Roche unveils data for Tecentriq/Avastin combo in kidney cancer

Patients on the combo had a lengthier PFS than those on Pfizer’s Sutent

Roche Basel Switzerland

Roche faces biosimilar blitz in 2018

Analysts predict copycat competitors will slow the Swiss group’s revenue growth

Roche Basel Switzerland

Roche’s autism drug scores FDA breakthrough status

Balovaptan could become the first drug to treat autism spectrum disorder

Roche Basel Switzerland

Roche wins CHMP backing for Hemlibra

Haemophilia A treatment on course for European approval

Roche Basel Switzerland

Roche’s Ocrevus is first primary progressive MS drug in EU

Analysts predict the drug could be a $3bn product by 2021

Roche and GE Healthcare plan ‘industry first’ digital platform

Co-developed clinical decision support software will begin with cancer and critical care

Roche Basel Switzerland

Roche buys cancer company Ignyta for $1.7bn

Pursues same oncology target that encouraged Bayer's recent deal with Loxo

Roche preps kidney cancer filing for Tecentriq/Avastin combo

Says treatment reduced risk of disease worsening compared to Sutent

- PMLiVE

Roche preps kidney cancer filing for Tecentriq/Avastin combo

Says treatment reduced risk of disease worsening compared to Sutent

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links